ASB 17061
Alternative Names: ASB-17061Latest Information Update: 27 May 2014
At a glance
- Originator Asubio Pharmaceuticals
- Class Skin disorder therapies
- Mechanism of Action Chymase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis
Most Recent Events
- 27 May 2014 Discontinued - Phase-II for Atopic dermatitis in USA (PO)
- 01 Jan 2014 Asubio Pharmaceuticals completes a phase II trial in Atopic dermatitis in USA (NCT01756898)
- 25 Nov 2013 Asubio Pharmaceuticals completes enrolment in its phase II trial for Atopic dermatitis in USA (NCT01756898)